MA29683B1 - COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATE - Google Patents

COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATE

Info

Publication number
MA29683B1
MA29683B1 MA30335A MA30335A MA29683B1 MA 29683 B1 MA29683 B1 MA 29683B1 MA 30335 A MA30335 A MA 30335A MA 30335 A MA30335 A MA 30335A MA 29683 B1 MA29683 B1 MA 29683B1
Authority
MA
Morocco
Prior art keywords
hyperplasie
benign
prostate
treating
combination
Prior art date
Application number
MA30335A
Other languages
French (fr)
Inventor
Helmut Haning
Peter Serno
Erwin Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA29683B1 publication Critical patent/MA29683B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Combinaison pour traiter une hyperplasie bénigne de la prostate Cette invention se rapporte à un nouveau procédé pour le traitement des symptômes associés à l'hyperplasie bénigne de la prostate couramment employé pour traiter médicalement l'hyperplasie bénigne de la prostate. Ceci nécessite l'utilisation concomitante : (1) d'un antagoniste des récepteurs (alpha)1-adrénergiques dans une formulation à libération contrôlée ou d'un inhibiteur de la 5-(alpha) réductase et (2) d'un inhibiteur de la PDE 5 spécifique de la GMPc dans une formulation à libération contrôlée ou d'un inhibiteur de la PDE 5 spécifique de la GMPc avec une longue demi-vie.This invention relates to a novel method for the treatment of symptoms associated with benign prostatic hyperplasia commonly used to medically treat benign prostatic hyperplasia. This requires the concomitant use of: (1) an (alpha) 1-adrenergic receptor antagonist in a controlled release formulation or a 5- (alpha) reductase inhibitor and (2) an inhibitor of cGMP-specific PDE in a controlled release formulation or cGMP-specific PDE inhibitor with a long half-life.

MA30335A 2005-04-13 2007-10-29 COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATE MA29683B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (en) 2005-04-13 2005-04-13 Combination therapy for benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
MA29683B1 true MA29683B1 (en) 2008-08-01

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30335A MA29683B1 (en) 2005-04-13 2007-10-29 COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATE

Country Status (22)

Country Link
EP (1) EP1888075A1 (en)
JP (1) JP2008535877A (en)
KR (1) KR20080007252A (en)
CN (1) CN101193638A (en)
AR (1) AR053575A1 (en)
AU (1) AU2006233567A1 (en)
BR (1) BRPI0610634A2 (en)
CA (1) CA2605224A1 (en)
CR (1) CR9427A (en)
DE (1) DE102005016981A1 (en)
DO (1) DOP2006000074A (en)
GT (1) GT200600145A (en)
IL (1) IL186604A0 (en)
MA (1) MA29683B1 (en)
MX (1) MX2007012567A (en)
PE (1) PE20061338A1 (en)
RU (1) RU2007141518A (en)
SV (1) SV2008002477A (en)
TN (1) TNSN07385A1 (en)
TW (1) TW200716122A (en)
UY (1) UY29473A1 (en)
WO (1) WO2006108519A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
JP2009520806A (en) * 2005-12-21 2009-05-28 ファイザー・プロダクツ・インク Pharmaceutical combination of PDE-5 inhibitor and 5-α reductase inhibitor
JP2009542648A (en) * 2006-07-07 2009-12-03 テバ ファーマシューティカル インダストリーズ リミティド Solid composition comprising tadalafil and at least one carrier
DE102007028869A1 (en) 2007-06-22 2008-12-24 Ratiopharm Gmbh A process for the preparation of a medicament containing tadalafil
WO2009076664A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
ES2527515T3 (en) 2007-12-13 2015-01-26 Vanda Pharmaceuticals Inc. Method and composition to treat a condition mediated by an alpha adrenoceptor
US8737368B2 (en) 2010-04-26 2014-05-27 Intel Corporation Method, apparatus and system for switching traffic streams among multiple frequency bands
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (en) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 Drug port cavity disintegrating tablet and preparation method thereof
EA033983B1 (en) * 2013-06-28 2019-12-17 Ханми Фарм. Ко., Лтд. Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
KR20240015735A (en) 2013-07-23 2024-02-05 세레니티 파마슈티컬즈 엘엘씨 Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
KR20150056443A (en) * 2013-11-15 2015-05-26 한미약품 주식회사 Composite formulation comprising tadalafil and amlodipine
BR112016030731A2 (en) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd COMPOSITE PREPARATION, AND, METHOD OF PREPARATION OF A COMPOSITE PREPARATION
MY181172A (en) * 2014-06-30 2020-12-21 Hanmi Pharm Ind Co Ltd Composite preparation comprising active ingredient-containing film coating layer
CN106659690B (en) * 2014-06-30 2020-08-18 韩美药品株式会社 Composite preparation comprising a film coating containing an active ingredient
ES2923438T3 (en) * 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Compositions comprising low doses of desmopressin in combination with an alpha-adrenergic receptor antagonist
MX2018011642A (en) * 2016-03-31 2019-03-14 Hanmi Pharm Ind Co Ltd Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate.
KR101835506B1 (en) * 2016-10-25 2018-03-07 주식회사 에스텍파마 Rapid-acting mixture of tablet containing dutasteride and tadalafil
CN108066347B (en) * 2016-11-16 2021-02-02 深圳万和制药有限公司 Orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride
KR101879133B1 (en) * 2017-07-11 2018-07-17 (주)동구바이오제약 Agents for preventing or treating urinary disease and preparing the same
TR201715231A2 (en) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
DE102005016981A1 (en) 2006-10-19
GT200600145A (en) 2007-04-10
AU2006233567A1 (en) 2006-10-19
IL186604A0 (en) 2008-01-20
MX2007012567A (en) 2007-12-10
CR9427A (en) 2007-12-17
EP1888075A1 (en) 2008-02-20
UY29473A1 (en) 2006-11-30
RU2007141518A (en) 2009-05-20
AR053575A1 (en) 2007-05-09
SV2008002477A (en) 2008-02-08
JP2008535877A (en) 2008-09-04
KR20080007252A (en) 2008-01-17
TNSN07385A1 (en) 2009-03-17
BRPI0610634A2 (en) 2010-07-13
DOP2006000074A (en) 2006-10-15
WO2006108519A1 (en) 2006-10-19
TW200716122A (en) 2007-05-01
CA2605224A1 (en) 2006-10-19
CN101193638A (en) 2008-06-04
PE20061338A1 (en) 2007-01-28

Similar Documents

Publication Publication Date Title
MA29683B1 (en) COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATE
MA31150B1 (en) VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND TREATMENT OF FIRST-STAGE TUMORS
ATE509019T1 (en) BENZODIAZEPINE PIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
FR16C0021I2 (en) AZETIDINES AS MEK INHIBITORS AND THEIR USE FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ATE556060T1 (en) MONOCYCLIC ANILIDE SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
MA30333B1 (en) AMINOTETRAHYDROPYRANES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES.
NO20054411L (en) Therapeutic agents comprising an anti-angiogenic agent in combination with an SRC inhibitor and their therapeutic use
TR200302309T4 (en) Beta-carboline derivatives as useful inhibitors of phosphodiesterase.
NO20072322L (en) Lactam compounds and their use as pharmaceutical agents
TW200505903A (en) CGRP receptor antagonists
DE60332604D1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
MA32684B1 (en) Picolinamide derivatives act as kinase inhibitors
ATE535514T1 (en) CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS
MA27556A1 (en) PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
NO20082880L (en) Inhibitors of C-MET and its use
ATE464305T1 (en) BICYCLIC ANILIDE SPIROLACTAMES AS ANTAGONISTS OF THE CGRP RECEPTOR
HRP20050529A2 (en) Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
MA29915B1 (en) SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS
DE60314603D1 (en) COMPOSITIONS NECESSARY AS PROTEIN KINASE INHIBITORS
EA200700251A1 (en) AMIDOCONOMINATION AND THEIR APPLICATION AS PHARMACEUTICAL FACILITIES
MX2007002311A (en) Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof.
DE602005024004D1 (en) AS BETA SEKRETASE (BACE) HEMMER USEFUL 2-AMINO-CHINAZOLINE DERIVATIVES
ATE516803T1 (en) ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS
NO20065442L (en) Amido compounds and their use as drugs
ATE532781T1 (en) 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS